

***VCN Biosciences initiates Part II of its on-going Phase 1 clinical trial with VCN-01 in pancreatic cancer patients.***

After evaluating the safety and tolerability of the systemic administration of VCN-01 in monotherapy in P-VCNA-001 Phase 1 trial, Part II of this study is designed to determine the safety and biological activity of combining VCN-01 and chemotherapy (gemcitabine and Abraxane®). Following an initial six to nine safety run-in, an additional number of patients may be enrolled for further evaluation of safety and activity of the treatment.